{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:57:45Z","timestamp":1776164265579,"version":"3.50.1"},"reference-count":182,"publisher":"Bentham Science Publishers Ltd.","issue":"5","funder":[{"DOI":"10.13039\/501100007131","name":"Changzhou Sci & Tech Program","doi-asserted-by":"publisher","award":["CJ20199007"],"award-info":[{"award-number":["CJ20199007"]}],"id":[{"id":"10.13039\/501100007131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,4,20]]},"abstract":"<jats:sec><jats:title>Aims:<\/jats:title><jats:p>The aim of this study is to provide an overview of several emerging anti-diabetic molecules.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background:<\/jats:title><jats:p>Diabetes is a complex metabolic disorder involving the dysregulation of glucose homeostasis at various levels. Insulin, which is produced by \u03b2-pancreatic cells, is a chief regulator of glucose metabolism, regulating its consumption within cells, which leads to energy generation or storage as glycogen. Abnormally low insulin secretion from \u03b2-cells, insulin insensitivity, and insulin tolerance lead to higher plasma glucose levels, resulting in metabolic complications. The last century has witnessed extraordinary efforts by the scientific community to develop anti-diabetic drugs, and these efforts have resulted in the discovery of exogenous insulin and various classes of oral anti-diabetic drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Despite these exhaustive anti-diabetic pharmaceutical and therapeutic efforts, long-term glycemic control, hypoglycemic crisis, safety issues, large-scale economic burden and side effects remain the core problems.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method:<\/jats:title><jats:p>The last decade has witnessed the development of various new classes of anti-diabetic drugs with different pharmacokinetic and pharmacodynamic profiles. Details of their FDA approvals and advantages\/disadvantages are summarized in this review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The salient features of insulin degludec, sodium-glucose co-transporter 2 inhibitors, glucokinase activators, fibroblast growth factor 21 receptor agonists, and GLP-1 agonists are discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion :<\/jats:title><jats:p>In the future, these new anti-diabetic drugs may have broad clinical applicability. Additional multicenter clinical studies on these new drugs should be conducted.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450120666191031104653","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T13:39:18Z","timestamp":1572529158000},"page":"445-457","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1901-195X","authenticated-orcid":true,"given":"Ping","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacology, 3rd Affiliated Hospital, Soochow University, Changzhou, Jiangsu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-915X","authenticated-orcid":true,"given":"Zhenyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, 3rd Affiliated Hospital, Soochow University, Changzhou, Jiangsu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-9329","authenticated-orcid":true,"given":"Xiaohong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, 3rd Affiliated Hospital, Soochow University, Changzhou, Jiangsu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2096-685X","authenticated-orcid":true,"given":"Hao","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, 3rd Affiliated Hospital, Soochow University, Changzhou, Jiangsu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s12325-019-00925-6","volume":"36","author":"Cheng A.Y.Y.","year":"2019","unstructured":"Cheng A.Y.Y.; Patel D.K.; Reid T.S.; Wyne K.; Differentiating basal insulin preparations: understanding how they work explains why they are different. Adv Ther 2019,36(5),1018-1030","journal-title":"Adv Ther"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.12782","volume":"19","author":"Heise T.","year":"2017","unstructured":"Heise T.; Mathieu C.; Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab 2017,19(1),3-12","journal-title":"Diabetes Obes Metab"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/338594a0","volume":"338","author":"Derewenda U.","year":"1989","unstructured":"Derewenda U.; Derewenda Z.; Dodson E.J.; Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature 1989,338(6216),594-596","journal-title":"Nature"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1515\/bchm3.1990.371.2.669","volume":"371","author":"Kr\u00fcger P.","year":"1990","unstructured":"Kr\u00fcger P.; Gilge G.; Cabuk Y.; Wollmer A.; Cooperativity and intermediate states in the T----R-structural transformation of insulin. Biol Chem Hoppe Seyler 1990,371(8),669-673","journal-title":"Biol Chem Hoppe Seyler"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1021\/bi00436a046","volume":"28","author":"Kaarsholm N.C.","year":"1989","unstructured":"Kaarsholm N.C.; Ko H.C.; Dunn M.F.; Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin, and miniproinsulin. Biochemistry 1989,28(10),4427-4435","journal-title":"Biochemistry"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1021\/bi3008609","volume":"52","author":"Steensgaard D.B.","year":"2013","unstructured":"Steensgaard D.B.; Schluckebier G.; Strauss H.M.; Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry 2013,52(2),295-309","journal-title":"Biochemistry"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40261-013-0096-7","volume":"33","author":"Korsatko S.","year":"2013","unstructured":"Korsatko S.; Deller S.; Koehler G.; A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U\/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig 2013,33(7),515-521","journal-title":"Clin Drug Investig"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","volume":"14","author":"Heise T.","year":"2012","unstructured":"Heise T.; Nosek L.; B\u00f8ttcher S.G.; Hastrup H.; Haahr H.; Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012,14(10),944-950","journal-title":"Diabetes Obes Metab"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.diabet.2017.10.001","volume":"44","author":"Bailey T.S.","year":"2018","unstructured":"Bailey T.S.; Pettus J.; Roussel R.; Morning administration of 0.4U\/kg\/day insulin glargine 300U\/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U\/mL in type 1 diabetes. Diabetes Metab 2018,44(1),15-21","journal-title":"Diabetes Metab"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2337\/dc10-1925","volume":"34","author":"Birkeland K.I.","year":"2011","unstructured":"Birkeland K.I.; Home P.D.; Wendisch U.; Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011,34(3),661-665","journal-title":"Diabetes Care"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2337\/dc10-1905","volume":"34","author":"Heise T.","year":"2011","unstructured":"Heise T.; Tack C.J.; Cuddihy R.; A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011,34(3),669-674","journal-title":"Diabetes Care"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(10)62305-7","volume":"377","author":"Zinman B.","year":"2011","unstructured":"Zinman B.; Fulcher G.; Rao P.V.; Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011,377(9769),924-931","journal-title":"Lancet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/j.1464-5491.2011.03547.x","volume":"29","author":"Home P.D.","year":"2012","unstructured":"Home P.D.; Meneghini L.; Wendisch U.; Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes. Diabet Med 2012,29(6),716-720","journal-title":"Diabet Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(12)60204-9","volume":"379","author":"Heller S.","year":"2012","unstructured":"Heller S.; Buse J.; Fisher M.; Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012,379(9825),1489-1497","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","volume":"379","author":"Garber A.J.","year":"2012","unstructured":"Garber A.J.; King A.B.; Del Prato S.; Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012,379(9825),1498-1507","journal-title":"Lancet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40266-013-0138-0","volume":"31","author":"Korsatko S.","year":"2014","unstructured":"Korsatko S.; Deller S.; Mader J.K.; Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs Aging 2014,31(1),47-53","journal-title":"Drugs Aging"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40268-014-0048-6","volume":"14","author":"Nakae R.","year":"2014","unstructured":"Nakae R.; Kusunoki Y.; Katsuno T.; Medium-term effects of insulin degludec on patients with type 1 diabetes mellitus. Drugs R D 2014,14(2),133-138","journal-title":"Drugs R D"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1507\/endocrj.EJ15-0245","volume":"63","author":"Urakami T.","year":"2016","unstructured":"Urakami T.; Kuwabara R.; Aoki M.; Okuno M.; Suzuki J.; Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes. Endocr J 2016,63(2),159-167","journal-title":"Endocr J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/dom.12588","volume":"18","author":"Heise T.","year":"2016","unstructured":"Heise T.; Bain S.C.; Bracken R.M.; Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial. Diabetes Obes Metab 2016,18(2),196-199","journal-title":"Diabetes Obes Metab"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"Heise T.","year":"2012","unstructured":"Heise T.; Hermanski L.; Nosek L.; Feldman A.; Rasmussen S.; Haahr H.; Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012,14(9),859-864","journal-title":"Diabetes Obes Metab"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/dom.12938","volume":"19","author":"Heise T.","year":"2017","unstructured":"Heise T.; N\u00f8rskov M.; Nosek L.; Kaplan K.; Famulla S.; Haahr H.L.; Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300\u2009U\/mL in type 1 diabetes. Diabetes Obes Metab 2017,19(7),1032-1039","journal-title":"Diabetes Obes Metab"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.2337\/dc11-2503","volume":"35","author":"Hirsch I.B.","year":"2012","unstructured":"Hirsch I.B.; Bode B.; Courreges J.P.; Insulin degludec\/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care 2012,35(11),2174-2181","journal-title":"Diabetes Care"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1210\/jc.2012-3249","volume":"98","author":"Mathieu C.","year":"2013","unstructured":"Mathieu C.; Hollander P.; Miranda-Palma B.; Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013,98(3),1154-1162","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/dme.12243","volume":"30","author":"Bode B.W.","year":"2013","unstructured":"Bode B.W.; Buse J.B.; Fisher M.; Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013,30(11),1293-1297","journal-title":"Diabet Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00125-013-3056-0","volume":"57","author":"Koehler G.","year":"2014","unstructured":"Koehler G.; Heller S.; Korsatko S.; Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study. Diabetologia 2014,57(1),40-49","journal-title":"Diabetologia"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/dom.12573","volume":"18","author":"Davies M.","year":"2016","unstructured":"Davies M.; Sasaki T.; Gross J.L.; Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial. Diabetes Obes Metab 2016,18(1),96-99","journal-title":"Diabetes Obes Metab"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00125-015-3648-y","volume":"58","author":"Nakamura T.","year":"2015","unstructured":"Nakamura T.; Sakaguchi K.; So A.; Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study. Diabetologia 2015,58(9),2013-2019","journal-title":"Diabetologia"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/dom.12463","volume":"17","author":"Heise T.","year":"2015","unstructured":"Heise T.; Nosek L.; Klein O.; Coester H.; Svendsen A.L.; Haahr H.; Insulin degludec\/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus. Diabetes Obes Metab 2015,17(7),659-664","journal-title":"Diabetes Obes Metab"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/dme.13068","volume":"34","author":"Hirsch I.B.","year":"2017","unstructured":"Hirsch I.B.; Franek E.; Mersebach H.; Bardtrum L.; Hermansen K.; Safety and efficacy of insulin degludec\/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). Diabet Med 2017,34(2),167-173","journal-title":"Diabet Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14656566.2017.1293652","volume":"18","author":"Takahashi H.","year":"2017","unstructured":"Takahashi H.; Nishimura R.; Onda Y.; Ando K.; Tsujino D.; Utsunomiya K.; Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: A randomized, cross-over, pilot study. Expert Opin Pharmacother 2017,18(4),335-342","journal-title":"Expert Opin Pharmacother"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/dom.12097","volume":"15","author":"Onishi Y.","year":"2013","unstructured":"Onishi Y.; Ono Y.; Rab\u00f8l R.; Endahl L.; Nakamura S.; Superior glycaemic control with once-daily insulin degludec\/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab 2013,15(9),826-832","journal-title":"Diabetes Obes Metab"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.diabres.2018.10.024","volume":"147","author":"Philis-Tsimikas A.","year":"2019","unstructured":"Philis-Tsimikas A.; Astamirova K.; Gupta Y.; Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract 2019,147,157-165","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/13696998.2017.1409228","volume":"21","author":"Evans M.","year":"2018","unstructured":"Evans M.; Billings L.K.; H\u00e5kan-Bloch J.; An indirect treatment comparison of the efficacy of insulin degludec\/liraglutide (IDegLira) and insulin glargine\/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. J Med Econ 2018,21(4),340-347","journal-title":"J Med Econ"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.2337\/dc12-2329","volume":"36","author":"Gough S.C.","year":"2013","unstructured":"Gough S.C.; Bhargava A.; Jain R.; Mersebach H.; Rasmussen S.; Bergenstal R.M.; Low-volume insulin degludec 200 units\/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the begin low volume trial. Diabetes Care 2013,36(9),2536-2542","journal-title":"Diabetes Care"},{"key":"ref=35","first-page":"660","volume":"56","author":"Mu Y.M.","year":"2017","unstructured":"Mu Y.M.; Guo L.X.; Li L.; The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial. Zhonghua Nei Ke Za Zhi 2017,56(9),660-666","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"Wysham C.","year":"2017","unstructured":"Wysham C.; Bhargava A.; Chaykin L.; Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 2 diabetes: the switch 2 randomized clinical trial. JAMA 2017,318(1),45-56","journal-title":"JAMA"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.diabres.2017.06.007","volume":"130","author":"Aso Y.","year":"2017","unstructured":"Aso Y.; Suzuki K.; Chiba Y.; Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-na\u00efve Japanese patients with type 2 diabetes: I\u2019D GOT trial. Diabetes Res Clin Pract 2017,130,237-243","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"Marso S.P.","year":"2017","unstructured":"Marso S.P.; McGuire D.K.; Zinman B.; Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med 2017,377(8),723-732","journal-title":"N Engl J Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/13696998.2017.1301943","volume":"20","author":"Hunt B.","year":"2017","unstructured":"Hunt B.; Mocarski M.; Valentine W.J.; Langer J.; Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. J Med Econ 2017,20(7),663-670","journal-title":"J Med Econ"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163350","volume":"11","author":"Kumar A.","year":"2016","unstructured":"Kumar A.; Franek E.; Wise J.; Niemeyer M.; Mersebach H.; Sim\u00f3 R.; Efficacy and safety of once-daily insulin degludec\/insulin aspart versus insulin glargine (u100) for 52 weeks in insulin-na\u00efve patients with type 2 diabetes: a randomized controlled trial. PLoS One 2016,11(10)","journal-title":"PLoS One"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/dme.12982","volume":"33","author":"Franek E.","year":"2016","unstructured":"Franek E.; Haluz\u00edk M.; Canecki Var\u017ei\u0107 S.; Twice-daily insulin degludec\/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-na\u00efve adults with Type 2 diabetes. Diabet Med 2016,33(4),497-505","journal-title":"Diabet Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.2337\/dc15-S010","volume":"38","year":"2015","unstructured":"American Diabetes Association. Approaches to glycemic treatment. Diabetes Care 2015,38(Suppl.),S41-S48","journal-title":"Diabetes Care"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/dom.12115","volume":"15","author":"Philis-Tsimikas A.","year":"2013","unstructured":"Philis-Tsimikas A.; Del Prato S.; Satman I.; Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab 2013,15(8),760-766","journal-title":"Diabetes Obes Metab"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/dom.12892","volume":"19","author":"Harris S.B.","year":"2017","unstructured":"Harris S.B.; Kocsis G.; Prager R.; Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab 2017,19(6),858-865","journal-title":"Diabetes Obes Metab"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/dme.13256","volume":"34","author":"Rodbard H.W.","year":"2017","unstructured":"Rodbard H.W.; Bode B.W.; Harris S.B.; Safety and efficacy of insulin degludec\/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-na\u00efve people with Type 2 diabetes: the DUAL IV trial. Diabet Med 2017,34(2),189-196","journal-title":"Diabet Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40262-016-0455-7","volume":"56","author":"Haahr H.","year":"2017","unstructured":"Haahr H.; Fita E.G.; Heise T.; A review of insulin degludec\/insulin aspart: Pharmacokinetic and pharmacodynamic properties and their implications in clinical use. Clin Pharmacokinet 2017,56(4),339-354","journal-title":"Clin Pharmacokinet"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"Wright E.M.","year":"2011","unstructured":"Wright E.M.; Loo D.D.; Hirayama B.A.; Biology of human sodium glucose transporters. Physiol Rev 2011,91(2),733-794","journal-title":"Physiol Rev"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","volume":"467","author":"Vrhovac I.","year":"2015","unstructured":"Vrhovac I.; Balen Eror D.; Klessen D.; Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 2015,467(9),1881-1898","journal-title":"Pflugers Arch"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"Rieg T.","year":"2014","unstructured":"Rieg T.; Masuda T.; Gerasimova M.; Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 2014,306(2),F188-F193","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"Vallon V.","year":"2017","unstructured":"Vallon V.; Thomson S.C.; Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 2017,60(2),215-225","journal-title":"Diabetologia"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"Vallon V.","year":"2011","unstructured":"Vallon V.; Platt K.A.; Cunard R.; SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011,22(1),104-112","journal-title":"J Am Soc Nephrol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4103\/ijem.IJEM_160_17","volume":"23","author":"Baruah M.P.","year":"2019","unstructured":"Baruah M.P.; Makkar B.M.; Ghatnatti V.B.; Mandal K.; Sodium glucose co-transporter-2 inhibitor: benefits beyond glycemic control. Indian J Endocrinol Metab 2019,23(1),140-149","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","volume":"16","author":"Bolinder J.","year":"2014","unstructured":"Bolinder J.; Ljunggren \u00d6.; Johansson L.; Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014,16(2),159-169","journal-title":"Diabetes Obes Metab"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","volume":"58","author":"Cefalu W.T.","year":"2015","unstructured":"Cefalu W.T.; Stenl\u00f6f K.; Leiter L.A.; Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia 2015,58(6),1183-1187","journal-title":"Diabetologia"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"Roden M.","year":"2015","unstructured":"Roden M.; Merker L.; Christiansen A.V.; Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: A double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol 2015,14,154","journal-title":"Cardiovasc Diabetol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1185\/03007995.2013.850066","volume":"30","author":"Stenl\u00f6f K.","year":"2014","unstructured":"Stenl\u00f6f K.; Cefalu W.T.; Kim K.A.; Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014,30(2),163-175","journal-title":"Curr Med Res Opin"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1517\/13543776.15.11.1531","volume":"15","author":"Handlon A.L.","year":"2005","unstructured":"Handlon A.L.; Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin Ther Pat 2005,15(11),1531-1540","journal-title":"Expert Opin Ther Pat"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"Ehrenkranz J.R.","year":"2005","unstructured":"Ehrenkranz J.R.; Lewis N.G.; Kahn C.R.; Roth J.; Phlorizin: a review. Diabetes Metab Res Rev 2005,21(1),31-38","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1124\/jpet.106.110296","volume":"320","author":"Katsuno K.","year":"2007","unstructured":"Katsuno K.; Fujimori Y.; Takemura Y.; Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007,320(1),323-330","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1124\/jpet.108.140210","volume":"327","author":"Fujimori Y.","year":"2008","unstructured":"Fujimori Y.; Katsuno K.; Nakashima I.; Ishikawa-Takemura Y.; Fujikura H.; Isaji M.; Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008,327(1),268-276","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1038\/ki.2010.511","author":"Isaji M.","year":"2011","unstructured":"Isaji M.; SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int Suppl 2011(120),S14-S19","journal-title":"Kidney Int Suppl"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13047","author":"Wang C.","year":"2018","unstructured":"Wang C.; Zhou Y.; Kong Z.; The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab 2018","journal-title":"Diabetes Obes Metab"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"Heerspink H.J.L.","year":"2018","unstructured":"Heerspink H.J.L.; Kosiborod M.; Inzucchi S.E.; Cherney D.Z.I.; Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018,94(1),26-39","journal-title":"Kidney Int"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Lytvyn Y.","year":"2017","unstructured":"Lytvyn Y.; Bjornstad P.; Udell J.A.; Lovshin J.A.; Cherney D.Z.I.; sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 2017,136(17),1643-1658","journal-title":"Circulation"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/dc15-2688","volume":"39","author":"Daniele G.","year":"2016","unstructured":"Daniele G.; Xiong J.; Solis-Herrera C.; Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 2016,39(11),2036-2041","journal-title":"Diabetes Care"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","volume":"54","author":"Scheen A.J.","year":"2015","unstructured":"Scheen A.J.; Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 2015,54(7),691-708","journal-title":"Clin Pharmacokinet"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/dme.13629","volume":"35","author":"Laffel L.M.B.","year":"2018","unstructured":"Laffel L.M.B.; Tamborlane W.V.; Yver A.; Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. Diabet Med 2018,35(8),1096-1104","journal-title":"Diabet Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","volume":"53","author":"Kasichayanula S.","year":"2014","unstructured":"Kasichayanula S.; Liu X.; Lacreta F.; Griffen S.C.; Boulton D.W.; Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 2014,53(1),17-27","journal-title":"Clin Pharmacokinet"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"Levey A.S.","year":"2011","unstructured":"Levey A.S.; de Jong P.E.; Coresh J.; The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011,80(1),17-28","journal-title":"Kidney Int"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc18-0623","volume":"41","author":"Mathieu C.","year":"2018","unstructured":"Mathieu C.; Dandona P.; Gillard P.; Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the depict-2 study): 24-week results from a randomized controlled trial. Diabetes Care 2018,41(9),1938-1946","journal-title":"Diabetes Care"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"Eriksson J.W.","year":"2018","unstructured":"Eriksson J.W.; Lundkvist P.; Jansson P.A.; Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 2018,61(9),1923-1934","journal-title":"Diabetologia"},{"key":"ref=72","first-page":"405","volume":"24","author":"Fernandez A.","year":"2018","unstructured":"Fernandez A.; Warton E.M.; Schillinger D.; Language barriers and LDL-C\/SBP control among Latinos with diabetes. Am J Manag Care 2018,24(9),405-410","journal-title":"Am J Manag Care"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.2337\/dc15-0811","volume":"38","author":"Matthaei S.","year":"2015","unstructured":"Matthaei S.; Catrinoiu D.; Celi\u0144ski A.; Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care 2015,38(11),2018-2024","journal-title":"Diabetes Care"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1060028017731111","volume":"52","author":"Coppenrath V.A.","year":"2018","unstructured":"Coppenrath V.A.; Hydery T.; Dapagliflozin\/saxagliptin fixed-dose tablets: a new sodium-glucose cotransporter 2 and dipeptidyl peptidase 4 combination for the treatment of type 2 diabetes. Ann Pharmacother 2018,52(1),78-85","journal-title":"Ann Pharmacother"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"Soga F.","year":"2018","unstructured":"Soga F.; Tanaka H.; Tatsumi K.; Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol 2018,17(1),132","journal-title":"Cardiovasc Diabetol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12872-017-0663-6","volume":"17","author":"Brown A.J.M.","year":"2017","unstructured":"Brown A.J.M.; Lang C.; McCrimmon R.; Struthers A.; Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. BMC Cardiovasc Disord 2017,17(1),229","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","volume":"20","author":"Hallow K.M.","year":"2018","unstructured":"Hallow K.M.; Helmlinger G.; Greasley P.J.; McMurray J.J.V.; Boulton D.W.; Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 2018,20(3),479-487","journal-title":"Diabetes Obes Metab"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod M.","year":"2017","unstructured":"Kosiborod M.; Cavender M.A.; Fu A.Z.; Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the cvd-real study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 2017,136(3),249-259","journal-title":"Circulation"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1507\/endocrj.EJ17-0545","volume":"65","author":"Furukawa S.","year":"2018","unstructured":"Furukawa S.; Miyake T.; Senba H.; The effectiveness of dapagliflozin for sleep-disordered breathing among Japanese patients with obesity and type 2 diabetes mellitus. Endocr J 2018,65(9),953-961","journal-title":"Endocr J"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1055\/a-0591-9442","volume":"50","author":"Forst T.","year":"2018","unstructured":"Forst T.; Alghdban M.K.; Fischer A.; Sequential treatment escalation with dapagliflozin and saxagliptin improves beta cell function in type 2 diabetic patients on previous metformin treatment: an exploratory mechanistic study. Horm Metab Res 2018,50(5),403-407","journal-title":"Horm Metab Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4158\/EP161323.OR","volume":"23","author":"Ekholm E.","year":"2017","unstructured":"Ekholm E.; Hansen L.; Johnsson E.; Combined treatment with saxagliptin plus dapagliflozin reduces insulin levels by increased insulin clearance and improves \u03b2-cell function. Endocr Pract 2017,23(3),258-265","journal-title":"Endocr Pract"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/1753-0407.12634","volume":"10","author":"Yang W.","year":"2018","unstructured":"Yang W.; Ma J.; Li Y.; Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial. J Diabetes 2018,10(7),589-599","journal-title":"J Diabetes"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"384","DOI":"10.23736\/S0026-4806.17.05048-0","volume":"108","author":"Gonz\u00e1lez-Ortiz M.","year":"2017","unstructured":"Gonz\u00e1lez-Ortiz M.; Grover-P\u00e1ez F.; D\u00edaz-Cruz C.; de J Pati\u00f1o-Laguna A, L\u00f3pez-Murillo LD, Mart\u00ednez-Abundis E. Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes. Minerva Med 2017,108(4),384-386","journal-title":"Minerva Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/14656566.2017.1317748","volume":"18","author":"Kato K.","year":"2017","unstructured":"Kato K.; Suzuki K.; Aoki C.; The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: A randomized, crossover, controlled clinical trial. Expert Opin Pharmacother 2017,18(8),743-751","journal-title":"Expert Opin Pharmacother"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/dom.12954","volume":"19","author":"Lundkvist P.","year":"2017","unstructured":"Lundkvist P.; Pereira M.J.; Katsogiannos P.; Sj\u00f6str\u00f6m C.D.; Johnsson E.; Eriksson J.W.; Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1\u2009year. Diabetes Obes Metab 2017,19(9),1276-1288","journal-title":"Diabetes Obes Metab"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","volume":"16","author":"Fadini G.P.","year":"2017","unstructured":"Fadini G.P.; Bonora B.M.; Zatti G.; Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol 2017,16(1),42","journal-title":"Cardiovasc Diabetol"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.23736\/S0391-1977.16.02550-5","volume":"43","author":"Gonz\u00e1lez-Ortiz M.","year":"2018","unstructured":"Gonz\u00e1lez-Ortiz M.; M\u00e9ndez-Del Villar M.; Mart\u00ednez-Abundis E.; Ram\u00edrez-Rodr\u00edguez A.M.; Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Minerva Endocrinol 2018,43(3),229-235","journal-title":"Minerva Endocrinol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2337\/dc15-1736","volume":"39","author":"Rosenstock J.","year":"2016","unstructured":"Rosenstock J.; Chuck L.; Gonz\u00e1lez-Ortiz M.; Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-na\u00efve type 2 diabetes. Diabetes Care 2016,39(3),353-362","journal-title":"Diabetes Care"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/dc15-1730","volume":"38","author":"Henry R.R.","year":"2015","unstructured":"Henry R.R.; Thakkar P.; Tong C.; Polidori D.; Alba M.; Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015,38(12),2258-2265","journal-title":"Diabetes Care"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1185\/03007995.2015.1067192","volume":"31","author":"Gavin J.R.","year":"2015","unstructured":"Gavin J.R.; Davies M.J.; Davies M.; Vijapurkar U.; Alba M.; Meininger G.; The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin 2015,31(9),1693-1702","journal-title":"Curr Med Res Opin"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1055\/a-0585-0145","volume":"68","author":"Kusunoki M.","year":"2018","unstructured":"Kusunoki M.; Natsume Y.; Miyata T.; Tsutsumi K.; Oshida Y.; Effects of concomitant administration of a dipeptidyl peptidase-4 inhibitor in japanese patients with type 2 diabetes showing relatively good glycemic control under treatment with a sodium glucose co-transporter 2 inhibitor. Drug Res (Stuttg) 2018,68(12),704-709","journal-title":"Drug Res (Stuttg)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1111\/dom.13267","volume":"20","author":"Harashima S.I.","year":"2018","unstructured":"Harashima S.I.; Inagaki N.; Kondo K.; Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study. Diabetes Obes Metab 2018,20(7),1770-1775","journal-title":"Diabetes Obes Metab"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/dom.13224","volume":"20","author":"Polidori D.","year":"2018","unstructured":"Polidori D.; Iijima H.; Goda M.; Maruyama N.; Inagaki N.; Crawford P.A.; Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab 2018,20(5),1321-1326","journal-title":"Diabetes Obes Metab"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2337\/dc16-2427","volume":"40","author":"Hollander P.","year":"2017","unstructured":"Hollander P.; Bays H.E.; Rosenstock J.; Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care 2017,40(5),632-639","journal-title":"Diabetes Care"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/oby.20663","volume":"22","author":"Bays H.E.","year":"2014","unstructured":"Bays H.E.; Weinstein R.; Law G.; Canovatchel W.; Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014,22(4),1042-1049","journal-title":"Obesity (Silver Spring)"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","volume":"16","author":"Pfeifer M.","year":"2017","unstructured":"Pfeifer M.; Townsend R.R.; Davies M.J.; Vijapurkar U.; Ren J.; Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol 2017,16(1),29","journal-title":"Cardiovasc Diabetol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/dom.12829","volume":"19","author":"Neal B.","year":"2017","unstructured":"Neal B.; Perkovic V.; Matthews D.R.; Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab 2017,19(3),387-393","journal-title":"Diabetes Obes Metab"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2337\/dc15-1995","volume":"39","author":"Peters A.L.","year":"2016","unstructured":"Peters A.L.; Henry R.R.; Thakkar P.; Tong C.; Alba M.; Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 2016,39(4),532-538","journal-title":"Diabetes Care"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/dia.2018.0169","volume":"20","author":"Osonoi T.","year":"2018","unstructured":"Osonoi T.; Gouda M.; Kubo M.; Arakawa K.; Hashimoto T.; Abe M.; Effect of canagliflozin on urinary albumin excretion in japanese patients with type 2 diabetes mellitus and microalbuminuria: a pilot study. Diabetes Technol Ther 2018,20(10),681-688","journal-title":"Diabetes Technol Ther"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","volume":"85","author":"Garvey W.T.","year":"2018","unstructured":"Garvey W.T.; Van Gaal L.; Leiter L.A.; Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism 2018,85,32-37","journal-title":"Metabolism"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1507\/endocrj.EJ17-0065","volume":"64","author":"Takebayashi K.","year":"2017","unstructured":"Takebayashi K.; Hara K.; Terasawa T.; Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial. Endocr J 2017,64(9),923-931","journal-title":"Endocr J"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.jdiacomp.2016.07.016","volume":"30","author":"Romera I.","year":"2016","unstructured":"Romera I.; Gomis R.; Crowe S.; Empagliflozin in combination with oral agents in young and overweight\/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials. J Diabetes Complications 2016,30(8),1571-1576","journal-title":"J Diabetes Complications"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2337\/dc16-0522","volume":"39","author":"Hadjadj S.","year":"2016","unstructured":"Hadjadj S.; Rosenstock J.; Meinicke T.; Woerle H.J.; Broedl U.C.; Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care 2016,39(10),1718-1728","journal-title":"Diabetes Care"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1124\/dmd.111.040675","volume":"39","author":"Kalgutkar A.S.","year":"2011","unstructured":"Kalgutkar A.S.; Tugnait M.; Zhu T.; Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos 2011,39(9),1609-1619","journal-title":"Drug Metab Dispos"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1124\/dmd.112.049551","volume":"41","author":"Miao Z.","year":"2013","unstructured":"Miao Z.; Nucci G.; Amin N.; Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos 2013,41(2),445-456","journal-title":"Drug Metab Dispos"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"Kuchay M.S.","year":"2018","unstructured":"Kuchay M.S.; Krishan S.; Mishra S.K.; Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (e-lift trial). Diabetes Care 2018,41(8),1801-1808","journal-title":"Diabetes Care"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","volume":"61","author":"Sattar N.","year":"2018","unstructured":"Sattar N.; Fitchett D.; Hantel S.; George J.T.; Zinman B.; Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME trial. Diabetologia 2018,61(10),2155-2163","journal-title":"Diabetologia"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2174\/1573399812666160613113556","volume":"13","author":"Levine M.J.","year":"2017","unstructured":"Levine M.J.; Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Curr Diabetes Rev 2017,13(4),405-423","journal-title":"Curr Diabetes Rev"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2147\/DDDT.S114932","volume":"11","author":"Cinti F.","year":"2017","unstructured":"Cinti F.; Moffa S.; Impronta F.; Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther 2017,11,2905-2919","journal-title":"Drug Des Devel Ther"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"Hsia D.S.","year":"2017","unstructured":"Hsia D.S.; Grove O.; Cefalu W.T.; An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2017,24(1),73-79","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/dom.13255","volume":"20","author":"Khouri C.","year":"2018","unstructured":"Khouri C.; Cracowski J.L.; Roustit M.; SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Diabetes Obes Metab 2018,20(6),1531-1534","journal-title":"Diabetes Obes Metab"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s12272-012-1201-9","volume":"35","author":"Park K.","year":"2012","unstructured":"Park K.; Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus. Arch Pharm Res 2012,35(12),2029-2033","journal-title":"Arch Pharm Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2337\/diab.45.2.223","volume":"45","author":"Matschinsky F.M.","year":"1996","unstructured":"Matschinsky F.M.; Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996,45(2),223-241","journal-title":"Diabetes"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2337\/diabetes.47.3.307","volume":"47","author":"Matschinsky F.M.","year":"1998","unstructured":"Matschinsky F.M.; Glaser B.; Magnuson M.A.; Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes 1998,47(3),307-315","journal-title":"Diabetes"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1126\/science.1084073","volume":"301","author":"Grimsby J.","year":"2003","unstructured":"Grimsby J.; Sarabu R.; Corbett W.L.; Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003,301(5631),370-373","journal-title":"Science"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1021\/jm8003202","volume":"51","author":"Bertram L.S.","year":"2008","unstructured":"Bertram L.S.; Black D.; Briner P.H.; SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1. J Med Chem 2008,51(14),4340-4345","journal-title":"J Med Chem"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.bmcl.2010.01.041","volume":"20","author":"Iino T.","year":"2010","unstructured":"Iino T.; Hashimoto N.; Hasegawa T.; Chiba M.; Eiki J.; Nishimura T.; Metabolic activation of N-thiazol-2-yl benzamide as glucokinase activators: Impacts of glutathione trapping on covalent binding. Bioorg Med Chem Lett 2010,20(5),1619-1622","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00125-007-0646-8","volume":"50","author":"Fyfe M.C.","year":"2007","unstructured":"Fyfe M.C.; White J.R.; Taylor A.; Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 2007,50(6),1277-1287","journal-title":"Diabetologia"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.bmcl.2012.11.018","volume":"23","author":"Park K.","year":"2013","unstructured":"Park K.; Lee B.M.; Kim Y.H.; Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus. Bioorg Med Chem Lett 2013,23(2),537-542","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1124\/mol.111.074401","volume":"80","author":"Eiki J.","year":"2011","unstructured":"Eiki J.; Nagata Y.; Futamura M.; Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol 2011,80(6),1156-1165","journal-title":"Mol Pharmacol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/j.bmcl.2016.10.088","volume":"27","author":"Xu J.","year":"2017","unstructured":"Xu J.; Lin S.; Myers R.W.; Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus. Bioorg Med Chem Lett 2017,27(9),2063-2068","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.bmcl.2016.10.085","volume":"27","author":"Xu J.","year":"2017","unstructured":"Xu J.; Lin S.; Myers R.W.; Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus. Bioorg Med Chem Lett 2017,27(9),2069-2073","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1021\/acsmedchemlett.6b00140","volume":"7","author":"Dransfield P.J.","year":"2016","unstructured":"Dransfield P.J.; Pattaropong V.; Lai S.; Novel series of potent glucokinase activators leading to the discovery of AM-2394. ACS Med Chem Lett 2016,7(7),714-718","journal-title":"ACS Med Chem Lett"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/cpdd.289","volume":"6","author":"Zhi J.","year":"2017","unstructured":"Zhi J.; Zhai S.; Boldrin M.; Dose-dependent effect of piragliatin, a glucokinase activator, on the qt interval following short-term multiple doses in patients with type 2 diabetes mellitus. Clin Pharmacol Drug Dev 2017,6(3),258-265","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=125","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5812607","author":"Wang P.","year":"2017","unstructured":"Wang P.; Liu H.; Chen L.; Duan Y.; Chen Q.; Xi S.; Effects of a novel glucokinase activator, hms5552, on glucose metabolism in a rat model of type 2 diabetes mellitus. J Diabetes Res 2017","journal-title":"J Diabetes Res"},{"key":"ref=126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172252","volume":"12","author":"Tsumura Y.","year":"2017","unstructured":"Tsumura Y.; Tsushima Y.; Tamura A.; TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models. PLoS One 2017,12(2)","journal-title":"PLoS One"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/13543776.2014.918957","volume":"24","author":"Filipski K.J.","year":"2014","unstructured":"Filipski K.J.; Pfefferkorn J.A.; A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014. Expert Opin Ther Pat 2014,24(8),875-891","journal-title":"Expert Opin Ther Pat"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"30253","DOI":"10.1074\/jbc.270.51.30253","volume":"270","author":"Terauchi Y.","year":"1995","unstructured":"Terauchi Y.; Sakura H.; Yasuda K.; Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem 1995,270(51),30253-30256","journal-title":"J Biol Chem"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0092-8674(95)90235-X","volume":"83","author":"Grupe A.","year":"1995","unstructured":"Grupe A.; Hultgren B.; Ryan A.; Ma Y.H.; Bauer M.; Stewart T.A.; Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell 1995,83(1),69-78","journal-title":"Cell"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1074\/jbc.274.1.305","volume":"274","author":"Postic C.","year":"1999","unstructured":"Postic C.; Shiota M.; Niswender K.D.; Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 1999,274(1),305-315","journal-title":"J Biol Chem"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s001250050666","volume":"40","author":"Velho G.","year":"1997","unstructured":"Velho G.; Blanch\u00e9 H.; Vaxillaire M.; Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997,40(2),217-224","journal-title":"Diabetologia"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jama.2013.283980","volume":"311","author":"Steele A.M.","year":"2014","unstructured":"Steele A.M.; Shields B.M.; Wensley K.J.; Colclough K.; Ellard S.; Hattersley A.T.; Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 2014,311(3),279-286","journal-title":"JAMA"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1172\/JCI117064","volume":"93","author":"Byrne M.M.","year":"1994","unstructured":"Byrne M.M.; Sturis J.; Cl\u00e9ment K.; Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 1994,93(3),1120-1130","journal-title":"J Clin Invest"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11154-010-9147-z","volume":"11","author":"Hussain K.","year":"2010","unstructured":"Hussain K.; Mutations in pancreatic \u00df-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus. Rev Endocr Metab Disord 2010,11(3),179-183","journal-title":"Rev Endocr Metab Disord"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1210\/en.2005-0377","volume":"146","author":"Efanov A.M.","year":"2005","unstructured":"Efanov A.M.; Barrett D.G.; Brenner M.B.; A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 2005,146(9),3696-3701","journal-title":"Endocrinology"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/sj.bjp.0706848","volume":"149","author":"Coope G.J.","year":"2006","unstructured":"Coope G.J.; Atkinson A.M.; Allott C.; Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats. Br J Pharmacol 2006,149(3),328-335","journal-title":"Br J Pharmacol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/2211-5463.12255","volume":"8","author":"Yellapu N.K.","year":"2018","unstructured":"Yellapu N.K.; Kandlapalli K.; Kandimalla R.; Adi P.J.; Conformational transition pathway of R308K mutant glucokinase in the presence of the glucokinase activator YNKGKA4. FEBS Open Bio 2018,8(8),1202-1208","journal-title":"FEBS Open Bio"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/dom.13338","volume":"20","author":"Zhu X.X.","year":"2018","unstructured":"Zhu X.X.; Zhu D.L.; Li X.Y.; Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic \u03b2-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab 2018,20(9),2113-2120","journal-title":"Diabetes Obes Metab"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejphar.2018.02.036","volume":"826","author":"Lei L.","year":"2018","unstructured":"Lei L.; Liu S.; Li Y.; The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection. Eur J Pharmacol 2018,826,17-23","journal-title":"Eur J Pharmacol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejmech.2017.07.051","volume":"139","author":"Wang Z.","year":"2017","unstructured":"Wang Z.; Shi X.; Zhang H.; Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation. Eur J Med Chem 2017,139,128-152","journal-title":"Eur J Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1016\/j.bmcl.2017.04.041","volume":"27","author":"Cheruvallath Z.S.","year":"2017","unstructured":"Cheruvallath Z.S.; Gwaltney S.L.; Sabat M.; Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators. Bioorg Med Chem Lett 2017,27(12),2678-2682","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"44681","DOI":"10.1038\/srep44681","volume":"7","author":"Min Q.","year":"2017","unstructured":"Min Q.; Cai X.; Sun W.; Identification of mangiferin as a potential Glucokinase activator by structure-based virtual ligand screening. Sci Rep 2017,7,44681","journal-title":"Sci Rep"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/cpdd.261","volume":"5","author":"Denney W.S.","year":"2016","unstructured":"Denney W.S.; Denham D.S.; Riggs M.R.; Amin N.B.; Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in patients with type 2 diabetes mellitus inadequately controlled on metformin-a randomized, crossover, active-controlled study. Clin Pharmacol Drug Dev 2016,5(6),517-527","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/dom.12586","volume":"18","author":"Katz L.","year":"2016","unstructured":"Katz L.; Manamley N.; Snyder W.J.; AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes Obes Metab 2016,18(2),191-195","journal-title":"Diabetes Obes Metab"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.nucmedbio.2014.12.003","volume":"42","author":"Jahan M.","year":"2015","unstructured":"Jahan M.; Johnstr\u00f6m P.; Nag S.; Synthesis and biological evaluation of [C]AZ12504948; a novel tracer for imaging of glucokinase in pancreas and liver. Nucl Med Biol 2015,42(4),387-394","journal-title":"Nucl Med Biol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1517\/13543776.2014.965680","volume":"24","author":"Agius L.","year":"2014","unstructured":"Agius L.; Lessons from glucokinase activators: the problem of declining efficacy. Expert Opin Ther Pat 2014,24(11),1155-1159","journal-title":"Expert Opin Ther Pat"},{"key":"ref=147","doi-asserted-by":"publisher","unstructured":"Sonoda J, Chen MZ, Baruch A. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Investig 2017; 30(2): \/j\/hmbci.2017.30.issue-2\/hmbci- 2017-0002\/hmbci-2017-0002.xml.","DOI":"10.1515\/hmbci-2017-0002"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"Ornitz D.M.","year":"2015","unstructured":"Ornitz D.M.; Itoh N.; The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol 2015,4(3),215-266","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tem.2014.10.002","volume":"26","author":"Owen B.M.","year":"2015","unstructured":"Owen B.M.; Mangelsdorf D.J.; Kliewer S.A.; Tissue-specific actions of the metabolic hormones FGF15\/19 and FGF21. Trends Endocrinol Metab 2015,26(1),22-29","journal-title":"Trends Endocrinol Metab"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"Gaich G.","year":"2013","unstructured":"Gaich G.; Chien J.Y.; Fu H.; The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013,18(3),333-340","journal-title":"Cell Metab"},{"key":"ref=151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058575","volume":"8","author":"Kharitonenkov A.","year":"2013","unstructured":"Kharitonenkov A.; Beals J.M.; Micanovic R.; Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One 2013,8(3)","journal-title":"PLoS One"},{"key":"ref=152","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065763","volume":"8","author":"Adams A.C.","year":"2013","unstructured":"Adams A.C.; Halstead C.A.; Hansen B.C.; LY2405319, an engineered fgf21 variant, improves the metabolic status of diabetic monkeys. PLoS One 2013,8(6)","journal-title":"PLoS One"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/dom.12408","volume":"17","author":"Kim J.H.","year":"2015","unstructured":"Kim J.H.; Bae K.H.; Choi Y.K.; Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function. Diabetes Obes Metab 2015,17(2),161-169","journal-title":"Diabetes Obes Metab"},{"key":"ref=154","first-page":"4750","volume":"8","author":"Lee J.H.","year":"2016","unstructured":"Lee J.H.; Kang Y.E.; Chang J.Y.; An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function. Am J Transl Res 2016,8(11),4750-4763","journal-title":"Am J Transl Res"},{"key":"ref=155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049345","volume":"7","author":"Hecht R.","year":"2012","unstructured":"Hecht R.; Li Y.S.; Sun J.; Rationale-based engineering of a potent long-acting fgf21 analog for the treatment of type 2 diabetes. PLoS One 2012,7(11)","journal-title":"PLoS One"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","volume":"17","author":"Sposito A.C.","year":"2018","unstructured":"Sposito A.C.; Berwanger O.; de Carvalho L.S.F.; Saraiva J.F.K.; GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol 2018,17(1),157","journal-title":"Cardiovasc Diabetol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1042\/bj0010028","volume":"1","author":"Moore B.","year":"1906","unstructured":"Moore B.; On the treatment of Diabetus mellitus by acid extract of duodenal mucous membrane. Biochem J 1906,1(1),28-38","journal-title":"Biochem J"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S0140-6736(64)90724-X","volume":"2","author":"Balsano F.","year":"1964","unstructured":"Balsano F.; Pitucco G.; Musca A.; Dinoto V.; New interpretation of oral glucose tolerance. Lancet 1964,2(7364),865","journal-title":"Lancet"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1530\/JOE-16-0056","volume":"230","author":"Bauer P.V.","year":"2016","unstructured":"Bauer P.V.; Duca F.A.; Targeting the gastrointestinal tract to treat type 2 diabetes. J Endocrinol 2016,230(3),R95-R113","journal-title":"J Endocrinol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0167-0115(03)00125-3","volume":"114","author":"Mortensen K.","year":"2003","unstructured":"Mortensen K.; Christensen L.L.; Holst J.J.; Orskov C.; GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003,114(2-3),189-196","journal-title":"Regul Pept"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"S197","DOI":"10.2337\/diabetes.53.suppl_3.S197","volume":"53","author":"Holst J.J.","year":"2004","unstructured":"Holst J.J.; Orskov C.; The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 2004,53(Suppl. 3),S197-S204","journal-title":"Diabetes"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40519-016-0352-y","volume":"22","author":"Guglielmi V.","year":"2017","unstructured":"Guglielmi V.; Sbraccia P.; GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products. Eat Weight Disord 2017,22(2),231-240","journal-title":"Eat Weight Disord"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","volume":"23","author":"Thornberry N.A.","year":"2009","unstructured":"Thornberry N.A.; Gallwitz B.; Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 2009,23(4),479-486","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=164","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5308582","author":"Wang Q.","year":"2018","unstructured":"Wang Q.; Long M.; Qu H.; DPP-4 inhibitors as treatments for type 1 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Res 2018","journal-title":"J Diabetes Res"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/j.1365-2265.2008.03510.x","volume":"71","author":"Lerche S.","year":"2009","unstructured":"Lerche S.; Soendergaard L.; Rungby J.; No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol (Oxf) 2009,71(4),500-506","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=166","first-page":"178","volume":"10","author":"Tran K.L.","year":"2017","unstructured":"Tran K.L.; Park Y.I.; Pandya S.; Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits 2017,10(4),178-188","journal-title":"Am Health Drug Benefits"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.2337\/dc13-S004","volume":"36","year":"2013","unstructured":"Executive summary: Standards of medical care in diabetes--2013. Diabetes Care 2013,36(Suppl. 1),S4-S10","journal-title":"Diabetes Care"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/dom.13120","volume":"20","author":"Hjerpsted J.B.","year":"2018","unstructured":"Hjerpsted J.B.; Flint A.; Brooks A.; Axelsen M.B.; Kvist T.; Blundell J.; Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab 2018,20(3),610-619","journal-title":"Diabetes Obes Metab"},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2337\/dc15-2479","volume":"39","author":"Nauck M.A.","year":"2016","unstructured":"Nauck M.A.; Petrie J.R.; Sesti G.; A phase 2, randomized, dose-finding study of the novel once-weekly human glp-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 2016,39(2),231-241","journal-title":"Diabetes Care"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"Meier J.J.","year":"2012","unstructured":"Meier J.J.; GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012,8(12),728-742","journal-title":"Nat Rev Endocrinol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12933-014-0142-7","volume":"13","author":"Saraiva F.K.","year":"2014","unstructured":"Saraiva F.K.; Sposito A.C.; Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol 2014,13,142","journal-title":"Cardiovasc Diabetol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.abb.2008.08.001","volume":"478","author":"Green B.D.","year":"2008","unstructured":"Green B.D.; Hand K.V.; Dougan J.E.; McDonnell B.M.; Cassidy R.S.; Grieve D.J.; GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008,478(2),136-142","journal-title":"Arch Biochem Biophys"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0167-0115(01)00300-7","volume":"102","author":"Golpon H.A.","year":"2001","unstructured":"Golpon H.A.; Puechner A.; Welte T.; Wichert P.V.; Feddersen C.O.; Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001,102(2-3),81-86","journal-title":"Regul Pept"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1479164113481817","volume":"10","author":"Gaspari T.","year":"2013","unstructured":"Gaspari T.; Welungoda I.; Widdop R.E.; Simpson R.W.; Dear A.E.; The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-\/-) mouse model. Diab Vasc Dis Res 2013,10(4),353-360","journal-title":"Diab Vasc Dis Res"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12933-016-0480-8","volume":"15","author":"Rizzo M.","year":"2016","unstructured":"Rizzo M.; Rizvi A.A.; Patti A.M.; Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol 2016,15(1),162","journal-title":"Cardiovasc Diabetol"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2337\/dc16-1580","volume":"40","author":"Kumarathurai P.","year":"2017","unstructured":"Kumarathurai P.; Anholm C.; Larsen B.S.; Effects of liraglutide on heart rate and heart rate variability: A randomized, double-blind, placebo-controlled crossover study. Diabetes Care 2017,40(1),117-124","journal-title":"Diabetes Care"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12933-016-0425-2","volume":"15","author":"Kumarathurai P.","year":"2016","unstructured":"Kumarathurai P.; Anholm C.; Nielsen O.W.; Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. Cardiovasc Diabetol 2016,15(1),105","journal-title":"Cardiovasc Diabetol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1253\/circj.CJ-13-1561","volume":"78","author":"Oyama J.","year":"2014","unstructured":"Oyama J.; Node K.; Incretin therapy and heart failure. Circ J 2014,78(4),819-824","journal-title":"Circ J"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1177\/0963689717721234","volume":"26","author":"Kim D.S.","year":"2017","unstructured":"Kim D.S.; Choi H.I.; Wang Y.; Luo Y.; Hoffer B.J.; Greig N.H.; A New Treatment Strategy for Parkinson\u2019s Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. Cell Transplant 2017,26(9),1560-1571","journal-title":"Cell Transplant"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0806720106","volume":"106","author":"Li Y.","year":"2009","unstructured":"Li Y.; Perry T.; Kindy M.S.; GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009,106(4),1285-1290","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12974-016-0661-0","volume":"13","author":"Chen F.","year":"2016","unstructured":"Chen F.; Wang W.; Ding H.; Yang Q.; Dong Q.; Cui M.; The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia. J Neuroinflammation 2016,13(1),204","journal-title":"J Neuroinflammation"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/dom.12926","volume":"19","author":"Monami M.","year":"2017","unstructured":"Monami M.; Nreu B.; Scatena A.; Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab 2017,19(9),1233-1241","journal-title":"Diabetes Obes Metab"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:58:24Z","timestamp":1695376704000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176311\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":182,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666191031104653","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}